MENU
+Compare
KYTX
Stock ticker: NASDAQ
AS OF
Feb 4, 04:59 PM (EDT)
Price
$3.07
Change
-$0.03 (-0.97%)
Capitalization
132.54M

KYTX Kyverna Therapeutics Forecast, Technical & Fundamental Analysis

Industry Biotechnology
KYTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for KYTX with price predictions
Feb 03, 2025

Momentum Indicator for KYTX turns negative, indicating new downward trend

KYTX saw its Momentum Indicator move below the 0 level on January 31, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator turned negative. In of the 15 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KYTX entered a downward trend on January 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KYTX's RSI Oscillator exited the oversold zone, of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for KYTX just turned positive on January 23, 2025. Looking at past instances where KYTX's MACD turned positive, the stock continued to rise in of 6 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KYTX advanced for three days, in of 37 cases, the price rose further within the following month. The odds of a continued upward trend are .

KYTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.438) is normal, around the industry mean (15.631). P/E Ratio (0.000) is within average values for comparable stocks, (89.728). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.841). KYTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (270.367).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KYTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
KYTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

KYTX is expected to report earnings to rise 18.75% to -94 cents per share on April 01

Kyverna Therapeutics KYTX Stock Earnings Reports
Q4'24
Est.
$-0.95
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.11
The last earnings report on November 13 showed earnings per share of -80 cents, beating the estimate of -83 cents. With 436.95K shares outstanding, the current market capitalization sits at 132.54M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
5980 Horton Street
Phone
+1 510 925-2492
Employees
96
Web
https://www.kyvernatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KSCOX189.052.31
+1.24%
Kinetics Small Cap Opportunities No Load
GLCUX34.38N/A
N/A
Goldman Sachs Large Cap Gr Insghts R6
CBLLX10.46-0.07
-0.66%
Allspring Large Cap Value Admin
ATHIX29.01-0.21
-0.72%
American Century Heritage I
HUMDX16.91-0.20
-1.17%
Huber Mid Cap Value Inv